ASCO GU 2017: Novel Imaging Modality: Radiographic Biopsy - Session Highlights

Orlando, Florida USA (UroToday.com) Dr. Mohamad E. Allaf noted that the histologic characterization of renal masses with currently available imaging is limited at best. This fact is validated by the 82% increase in benign mass excision seen over the last decade (Johnson et al. J Urol. 2015).

ASCO GU 2017: Contemporary Role of Percutaneous Biopsy for the Small Renal Mass - Session Highlights

Orlando, Florida USA (UroToday.com) Dr. Alessandro Volpe reported that renal mass biopsy (RMB) is still controversial for the diagnosis of small renal masses (SRMs), with the reasons being doubts regarding its safety, technique, and efficacy. However, he noted that RMB requires only local anesthesia, uses ultrasonographic guidance, is an outpatient procedure, and leads to only minimal pain.

ASCO GU 2017: The Evolving Role of Active Surveillance in Small Renal Tumors - Session Highlights

Orlando, Florida USA (UroToday.com) Dr. Smaldone Marc discussed the role of active surveillance (AS) in small renal masses (SRMs, tumors < 4 cm). The incidence of renal cell carcinoma is rising, largely due to the increasing use of cross-sectional imaging, and most of that increased frequency has occurred with SRMs.

ASCO GU 2017: Genetic Conditions With a Predisposition to Renal Cell Carcinoma - Session Highlights

Orlando, Florida USA (UroToday.com) Dr. W. Marston Linehan, Chief of the Urologic Oncology Branch at the National Cancer Institute, gave the keynote lecture in renal cell carcinoma (RCC). The focus of his talk was genetic conditions that predispose to RCC.

ASCO GU 2017: Con: Is There a Role for Treatment Intensification for Patients With Poor Prognosis Germ-Cell Tumors With Unfavorable Marker Decline? - Session Highlights

Orlando, Florida USA (UroToday.com) Dr. George Bosi noted that the standards of treatment for poor-risk nonseminomatous germ-cell tumors are either bleomycin, etoposide, and cisplatin or etoposide, ifosfamide, and cisplatin x 4, with overall survival (OS) at 5 years being 50%.

ASCO GU 2017: Debate - Pro: Is There a Role for Treatment Intensification for Patients With Poor Prognosis Germ-Cell Tumors With Unfavorable Marker Decline? - Session Highlights

Orlando, Florida USA (UroToday.com) According to Dr. Karim Fizazi, the management of International Germ Cell Cancer Collaborative Group’s poor-risk patients with nonseminomatous germ-cell tumor (NSGCT) is, perhaps, one of the most difficult aspects of advanced testis cancer care. Such patients are characterized by high tumor-marker levels, nonpulmonary visceral metastases, or primary mediastinal tumors.

ASCO GU 2017: Actionable targets in germ cell tumors - Session Highlights

Orlando, Florida USA (UroToday.com) I80% of GCT patient will be cured with platinum based chemotherapy. On the other hand, resistant disease occurs in about 20% of cases of advanced GCT. The unmet needs in this space are to better understand the biology of GCT and incorporate this biology into treatment with novel therapies.
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe